OncoMatch/Clinical Trials/NCT06835972
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Is NCT06835972 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Abemaciclib and Cabozantinib for metastatic renal cell carcinoma.
Treatment: Abemaciclib · Cabozantinib — The researchers are doing this study to find out whether the combination of abemaciclib and cabozantinib is a safe and effective treatment for people with metastatic clear cell renal cell carcinoma (ccRCC) and translocation-associated renal cell cancer (tRCC). The researchers will test different doses of the study drugs to find the highest doses that cause few or mild side effects in participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy
Patient must have progressed on 1 prior PD-1 or PD-L1 targeted treatment
Must have received: VEGFR inhibitor
Patient must have progressed on ... prior VEGFR directed TKI therapy
Cannot have received: CDK4/6 inhibitor (abemaciclib)
Prior treatment with abemaciclib
Cannot have received: VEGFR inhibitor (cabozantinib)
Prior treatment with ... cabozantinib
Lab requirements
Blood counts
ANC ≥ 1500/μL (no G-CSF within 2 weeks); WBC ≥ 2500/μL and ≤ 15,000/μL (no G-CSF); absolute lymphocyte count > 0.5K/mcL; platelets ≥ 100,000/μL (no transfusion within 2 weeks); hemoglobin ≥ 9.0 g/dL (no transfusion within 2 weeks); PT/INR or PTT < 1.3x ULN
Kidney function
eGFR ≥ 30 mL/min (CKD-EPI); urine protein/creatinine ratio ≤ 1.8 mg/mg
Liver function
ALT, AST, and ALP ≤ 3 X ULN (ALP ≤ 5 x ULN if bone metastases); serum bilirubin ≤ 1.5 x ULN (≤ 2 x ULN if Gilbert disease); serum albumin ≥ 2.8 g/dl
Cardiac function
LVEF ≥ 50% by echocardiogram (ECHO); QTcF ≤ 470 ms
Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment: ... LVEF < 50% by echocardiogram (ECHO) [excluded]; QTcF > 470 ms per ECG [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University (Data Collection Only) · Baltimore, Maryland
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify